On Statistical Relationship between ADRA2A Expression and the Risk of Breast Cancer Relapse

Shkurnikov, M. Yu.; Galatenko, Vladimir; Lebedev, A. V.; Podolskii, Vladimir V.; Тоневицкий, Е. А.; Maltseva, D. V.

doi:10.1007/s10517-014-2589-7

Cited by 9 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies conducted using cDNA microarrays reported the presence of SQLE in sets of differentially expressed transcripts in breast cancers [6] and lung squamous cell carcinoma [7]. Recent studies have shown that SQLE is differentially expressed in lung cancer [7,8], breast cancer [9,10], prostate cancer [11,12], hepatocellular carcinoma [13], and esophageal cancer [14]. SQLE overexpression or copy number variation is significantly associated with tumor progression, metastases and unfavorable outcomes in prostate cancer and breast cancer patients [6,15,16].…”

Section: Introductionmentioning

confidence: 99%

Squalene Epoxidase Correlates E-Cadherin Expression and Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features

Kim

Kang

2019

JCM

View full text Add to dashboard Cite

Squalene epoxidase (SE), coded by SQLE, is an important rate-limiting enzyme in the cholesterol biosynthetic pathway. Recently, the aberrant expression of SQLE, which is responsible for epithelial to mesenchymal transition (EMT), has been reported in various types of cancer. This study was undertaken to clarify the clinicopathologic implications of SE in patients with stage I to IV colorectal cancer (CRC). We also analyzed the expression patterns of SE in association with E-cadherin in a series of CRCs. We detected the cytoplasmic expression of SE in 59.4% of carcinoma samples by immunohistochemistry (IHC). There was a significant correlation between a high level of SE expression and lymphovascular (LV) invasion (p < 0.001), tumor budding (p < 0.001), invasion depth (p = 0.002), regional lymph node metastasis (p < 0.001), and pathologic TNM stage (p < 0.001). SE is more abundantly expressed at the invasive front, and reversely correlated with E-cadherin expression. Patients with SE-positive CRC had shorter recurrence-free survival (RFS) and poor overall survival (OS) than those with SE-negative CRC in multivariate analysis (p < 0.001 and p < 0.001, respectively). These data suggest that SE can serve as a valuable biomarker for unfavorable prognosis, and as a possible therapeutic target in CRCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Squalene Epoxidase Correlates E-Cadherin Expression and Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features

Kim

Kang

2019

JCM

View full text Add to dashboard Cite

show abstract

“…Several studies have already been conducted to explore the potential role of the dysregulation of SQLE in BC (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). Polycarpou-Schwarz et al (16) identified a new microprotein gene, Cancer-Associated Small Integral Membrane Open reading frame 1 (CASIMO1), utilizing a microarray approach.…”

Section: Discussionmentioning

confidence: 99%

“…Kim et al (21) found that SQLE was one of the important genes for BC metastasis based on a standardized pathway-based approach. Shkurnikov et al (22) searched for novel parameters predicting the risk of relapse in patients with BC using public microarray datasets, revealing that SQLE expression was significantly associated with the risk of relapse in patients with BC. Parada et al (23) examined racial differences in the expression levels of eight genes, including SQLE, and their associations with the risk of BC recurrence among white and black women with BC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Squalene epoxidase expression is associated with breast tumor progression and with a poor prognosis in breast cancer

et al. 2021

View full text Add to dashboard Cite

Differentially expressed genes (DEGs) have been previously identified using massive parallel RNA sequencing in matched normal, breast cancer (BC) and nodal metastatic tissues. Squalene epoxidase (SQLE), one of these DEGs, is a key enzyme in cholesterol synthesis. The aim of the present study was to investigate the potential involvement of SQLE in the tumorigenic process of BC and to determine its association with the clinical outcome of BC. SQLE mRNA expression was measured using reverse transcription-quantitative PCR in 10 pairs of ductal carcinoma in situ (DCIS) and BC tissues and their adjacent normal tissues. Immunohistochemical staining of SQLE on tissue microarray was performed in 26 normal breast, 79 DCIS and 198 BC samples. The role of SQLE as a prognostic biomarker in patients with BC has been verified using BreastMark. SQLE mRNA expression was significantly increased in DCIS and BC tissues compared with that in their adjacent normal tissues. High SQLE expression was detected in 0, 48.1 and 40.4% of normal breast, DCIS and BC tissues, respectively. SQLE expression in DCIS and BC tissues was significantly higher than that in normal breast tissues. High SQLE expression was observed in DCIS with higher nuclear grade, comedo-type necrosis and HER2 positivity. High SQLE expression in BC was associated with larger tumor size, nodal metastases, higher stage, HER2 subtype and distant metastatic relapse. High SQLE expression was associated with poor disease-free and overall survival, and independently predicted poor disease-free survival in patients with BC. Following BreastMark analysis, high SQLE mRNA expression in BC was significantly associated with a poor prognosis in the ‘all’, lymph node negative, lymph node positive, luminal A subtype and luminal B subtype groups. Therefore, SQLE expression may be upregulated during the tumorigenic process of BC, and high SQLE expression may be a useful biomarker for predicting a poor prognosis in patients with BC.

show abstract

“…Several reports [24,28] showed that stimulation of α2-adrenoceptors by the highly selective α2-adrenoceptor agonists dexmedetomidine and clonidine enhance breast cancer cell proliferation, tumor growth, and metastasis, and this could be reversed by the α2-adrenoceptor antagonists yohimbine and rauwolscine. In addition, Shkurnikov and colleagues [29] found a significant correlation between the risk of breast cancer relapse and expression of α2A-adrenoceptors. The mechanism of α2-adrenoceptor-modulating cancer progression has not yet been clearly elucidated.…”

Section: β-Adrenoceptor Modulatorsmentioning

confidence: 99%

Adrenoceptor modulators and cancer progression

Hirota

2016

J Anesth

View full text Add to dashboard Cite

only β2-receptors in ovarian and prostatic cancer tissues [6]. Therefore, β-adrenergic stimulation may worsen the prognosis of cancer patients.In contrast, inhibition of β-adrenoceptors might improve prognosis. Stiles and colleagues [7] reported that β-blockers could induce apoptosis in angiosarcoma cells in vitro and also inhibit proliferation of angiosarcoma. However, the data of clinical studies are controversial. Although De Giorgi and colleagues [8] reported that β-blockers may protect against melanoma recurrence and death, McCourt and colleagues [9] found that β-blockers did not reduce the risk of death from melanoma. Heitz and colleagues [10] also reported that survival did not differ between platinum-sensitive recurrent ovarian cancer patients with or without β-blocker medication. In addition, β-blockers may not reduce the risk of cancer recurrence and death in patients with colorectal cancer, breast cancer, malignant melanoma, lung cancer, and prostate cancer [11][12][13][14][15][16]. Thus, β-blocker efficacy in cancer for recurrence and death remains controversial.In a retrospective analysis of long-term propranolol use on hepatocellular carcinoma (HCC) incidence in patients with HCV-associated cirrhosis, Nkontchou and colleagues [17] found a decreased HCC risk. Using epidemiological methods and meta-analysis, Monami and colleagues [18] studied the relationship between β-blocker medication and cancer incidence. Both analyses suggest that β-blockers may reduce the risk of cancer development. Therefore, β-blockers might exert preventive effects against cancer incidence. α-Adrenoceptor modulatorsIt has been reported that α1-adrenoceptors are expressed in prostate cancer [19][20][21], malignant mesothelioma

show abstract

On Statistical Relationship between ADRA2A Expression and the Risk of Breast Cancer Relapse

Cited by 9 publications

References 14 publications

Squalene Epoxidase Correlates E-Cadherin Expression and Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features

Squalene Epoxidase Correlates E-Cadherin Expression and Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features

Squalene epoxidase expression is associated with breast tumor progression and with a poor prognosis in breast cancer

Adrenoceptor modulators and cancer progression

Contact Info

Product

Resources

About